Apellis Pharmaceuticals, Inc. (APLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$41.030.00%
Close 2026-05-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put APLS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 42% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 1% on a typical day and fell roughly 44% in its worst 12-month stretch.
View RiskAPLS's growth depends on maintaining strong financial performance in a supportive healthcare sector. Recent financial performance is holding in the top half of its industry. The company trades at a valuation above typical for the sector. This suggests that expectations may be high. Management is running behind on a stated commitment, which raises risk. Our model puts the next-quarter miss probability near 34%. Peer multiples imply a price about 23% above where it trades. This read is provisional.
Trailing returns as of 2026-05-14. APLS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering APLS (as of May 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare APLS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| APLS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put APLS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Completion of Acquisition by Biogen
Acquisition completion aligns with strategic growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-05-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.